You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
特寶生物(688278.SH)半年度淨利潤升199.81%至4661.18萬元
格隆匯 08-17 18:38

格隆匯 8 月 17日丨特寶生物(688278.SH)發佈2020年半年度報告,實現營業收入3.60億元,同比增長12.83%;歸屬於上市公司股東的淨利潤4661.18萬元,同比增長199.81%;歸屬於上市公司股東的扣除非經常性損益的淨利潤4355.33萬元,同比增長105.81%;基本每股收益0.12元。

公司自成立以來,持續專注於重組蛋白質及其長效修飾藥物領域,通過持續創新不斷優化產品線,為患者提供更多樣化的用藥選擇,不斷提升核心競爭力和拓寬行業護城河。報告期內,公司根據戰略部署穩步推進6個重點研發項目,其中:“Y型聚乙二醇重組人生長激素(YPEG-GH)”和“Y型聚乙二醇重組人粒細胞刺激因子(YPEG-G-CSF)”正開展III期臨牀研究;“Y型聚乙二醇重組人促紅素(YPEG-EPO)”已獲得II期臨牀試驗通知書,即將召開臨牀啟動會;“ACT50和“ACT60”正開展藥學和臨牀前研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account